Enliven Therapeutics, Inc. · NASDAQ:ELVN
Venrock Healthcare Capital Partners III, L.P.'s stake in Enliven Therapeutics, Inc. fell to 2.80% (Schedule 13G/A)
Event Mar 31, 2026 · Filed May 15, 2026
Venrock Healthcare Capital Partners III, L.P.'s stake in Enliven Therapeutics, Inc. fell to 2.80%, 1,726,331 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G/A).
- Stake
- 2.80%
- Shares
- 1,726,331
- Intent
- Passive
- What changed
- Fell below 5%
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 2.80% | 1,726,331 |
| VHCP Co-Investment Holdings III, LLC | 2.80% | 1,726,331 |
| Venrock Healthcare Capital Partners EG, L.P. | 2.80% | 1,726,331 |
| VHCP Management III, LLC | 2.80% | 1,726,331 |
| VHCP Management EG, LLC | 2.80% | 1,726,331 |
| Nimish Shah | 2.80% | 1,726,331 |
| Bong Y. Koh | 2.80% | 1,726,331 |
Source
Related
- Enliven Therapeutics, Inc.
- Venrock Healthcare Capital Partners III, L.P.
- Enliven Therapeutics, Inc. shareholders
- Schedule 13G/A · Venrock Healthcare Capital Partners III, L.P. · Nov 14, 2025
- Form 4 · Hohl Benjamin · Oct 21, 2026
- Form 4 · Collins Helen Louise · Oct 21, 2026
- Form 4 · Garland J. Scott · Oct 5, 2026
- Form 4 · Hohl Benjamin · Sep 21, 2026
- Form 4 · Collins Helen Louise · Sep 21, 2026